Benzinga | Aug 19, 2021 07:34AM EDT

Calliditas Therapeutics Earlier Reported Q2 EPS $(0.38) Beats $(0.48) Estimate

Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 153.33 percent decrease over losses of $(0.15) per share from the same period last year.